Purpose of the study: To compare the difference in the effect of DBM and Busulfan- As single agents and combined with Cytosine arabinoside (Ara-C) and Cyclophosphamide (CP) - on the bone marrow and small intestinal mucosa. Materials and methods: Our study was performed on Balb/c mice. The applied doses of the selected agents: DBM (3x500 mg/kg/dpo.), Busulfan (1x45 mg/kg/dpo.), CP (lOOmg/kg ip.), Ara-C (1000 mg/kg ip.) and in combination: DBM (3x100 and 3x500 mg/kg/d) or (Busulfan 3x15 and 3x30 mg/kg/d po.) with Ara-C (3x300 mg/kg/d ip.) and CP (3x100 mg/kg/d ip.) in 8-9 days. The femoral DNA content was measured by micro- flurocytometric DNA analysis with Hoechst-33258 reagent, the damage of the small intestinal mucosa was studied by determination of the thymidine kinase activity. Results: After application of DBM and Ara-C as single agents, the DNA content of the femoral bone marrow dropped shortly, but recovered in several days. In the case of Ara-C the decrease was similar, but there was only a transient recovery, folloived by persistent low level of DNA. After application of Busulfan there was a late persistent low DNA level. Combined therapy containing low or high dose of Busulfan or DBM resulted in a permanent decrease of DNA with high mortality rate after high dose. Thymidine kinase activity of small intestinal mucosa decreased temporally immediately after application of Busulfan and DBM as monotherapy, followed by a quick (>200%) recovery. Conclusion: After the application of DBM or Busulfan in combination with CP and Ara-C there was no difference in the decrease of DNA content of the femoral bone marroiv (in spite of the difference found after monotherapy). The damage of the small intestinal mucosa characterised by the decrease of thymidine kinase activity was fairly similar after the DBM and Busulfan monotherapy.
|Number of pages||5|
|Publication status||Published - Dec 1 1999|
ASJC Scopus subject areas